Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 26;9(6):604. doi: 10.3390/biomedicines9060604

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Sensitivity Analyses—Cumulative Incidence of AECOPD. (a) Cumulative incidence of AECOPD in MTX users and non-MTX users in the unmatched population at 180-day follow-up. MTX was associated with lower risk of hospitalization-requiring COPD exacerbation (HR 0.76, CI 0.59–0.99, p = 0.04); (b) Cumulative incidence of AECOPD in MTX users and non-MTX users in the matched population at 365-day follow-up. MTX was associated with lower risk of hospitalization-requiring COPD exacerbation (HR 0.81, CI 0.81–0.82, p < 0.001); (c) Cumulative incidence of AECOPD for MTX users and non-MTX users in the unmatched population at 365-day follow-up. MTX was associated with lower risk of hospitalization-requiring COPD exacerbation (HR 0.92, CI 0.76–1.11, p = 0.37). COPD, Chronic Obstructive Pulmonary Disease; AECOPD, Acute hospitalization-requiring exacerbation of COPD; MTX, Methotrexate; HR, Hazard ratio; CI, Confidence interval.

Sensitivity Analyses—Cumulative Incidence of AECOPD. (a) Cumulative incidence of AECOPD in MTX users and non-MTX users in the unmatched population at 180-day follow-up. MTX was associated with lower risk of hospitalization-requiring COPD exacerbation (HR 0.76, CI 0.59–0.99, p = 0.04); (b) Cumulative incidence of AECOPD in MTX users and non-MTX users in the matched population at 365-day follow-up. MTX was associated with lower risk of hospitalization-requiring COPD exacerbation (HR 0.81, CI 0.81–0.82, p < 0.001); (c) Cumulative incidence of AECOPD for MTX users and non-MTX users in the unmatched population at 365-day follow-up. MTX was associated with lower risk of hospitalization-requiring COPD exacerbation (HR 0.92, CI 0.76–1.11, p = 0.37). COPD, Chronic Obstructive Pulmonary Disease; AECOPD, Acute hospitalization-requiring exacerbation of COPD; MTX, Methotrexate; HR, Hazard ratio; CI, Confidence interval.